• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Serzone (nefazodone HCl) Feb 2003

Audience: Neuropsychiatric healthcare professionals and Pharmacists

Bristol-Myers Squibb notified healthcare professionals of medication errors due to name confusion between Serzone, indicated for the treatment of depression, and Seroquel, a product of AstraZeneca, indicated for the treatment of schizophrenia. The overlapping strengths (100 mg and 200 mg), the dosage form (tablets), the dosing interval (BID), and the fact that these two products are stocked close together in pharmacies were critical in causing these medication errors.

[December 9, 2002 - Letter - Bristol-Myers Squibb] 

Past MedWatch alerts:
[May 20, 2002 - Letter - AstraZeneca] (Seroquel alert)